Daewoong Pharmaceutical Co., Ltd (KRX:069620)

South Korea flag South Korea · Delayed Price · Currency is KRW
160,600
-2,400 (-1.47%)
At close: Jun 5, 2025, 3:30 PM KST
47.34%
Market Cap 1.85T
Revenue (ttm) 1.44T
Net Income (ttm) 38.48B
Shares Out 11.51M
EPS (ttm) 3,344.54
PE Ratio 48.02
Forward PE 15.15
Dividend 600.00 (0.37%)
Ex-Dividend Date Dec 27, 2024
Volume 49,383
Average Volume 52,872
Open 162,700
Previous Close 163,000
Day's Range 159,500 - 163,100
52-Week Range 100,100 - 171,600
Beta 0.47
RSI 65.22
Earnings Date May 14, 2025

About Daewoong Pharmaceutical

Daewoong Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was founded in 1945 and... [Read more]

Sector Healthcare
Founded 1945
Employees 1,727
Stock Exchange Korea Stock Exchange
Ticker Symbol 069620
Full Company Profile

Financial Performance

In 2024, Daewoong Pharmaceutical's revenue was 1.42 trillion, an increase of 3.44% compared to the previous year's 1.38 trillion. Earnings were 24.73 billion, a decrease of -79.68%.

Financial Statements

News

Sun Pharma launches FEXUCLUE 40 mg in India for treatment of Erosive Esophagitis

Sun Pharmaceutical Industries Limited has announced the launch of FEXUCLUE® (Fexuprazan) 40 mg tablets in India, a novel treatment for Erosive Esophagitis. FEXUCLUE® is a Potassium-Competitive Acid Bl...

2 months ago - Business Upturn